News
Zongertinib NDA Submitted in Japan
Nippon Boehringer Ingelheim that it has submitted a new drug application in Japan for zongertinib for the treatment of HER2 positive unresectable advanced or relapsed non-small cell lung cancer
The compound, also known as BI 1810631, has received orphan drug designation from the Japanese health ministry. It is an irreversible HER2-selective tyrosine kinase inhibitor, which is currently also under regulatory review in the US and China.
Condition: NSCLC/HER 2
Type: drug
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.